• About us
• Contact

Advertisement

Organisation › Details

Horizon Discovery Ltd.

Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary technology, GENESIS, is the world's most precise genome editing technology. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Horizon has harnessed GENESIS to create over 400 X-MAN cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease. In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms. *

 

	Start	2007-06-01 established
	Group	PerkinElmer (Group)
	Industry	drug discovery
	Person	Disley, Darrin M. (Mogrify 201902– CEO of Cell Mogrify Ltd before 11 years at Horizon Discovery)
	Street	Building 7300 IQ Cambridge
	City	CB25 9TL Waterbeach, Cambridgeshire
	Tel	+44-1223-655580
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for PerkinElmer (Group)

• [1] CN Bio Innovations Ltd.. (12/19/22). "Press Release: CN Bio Appoints Dr Paul Brooks as Chief Executive Officer". Cambridge....
• [2] PerkinElmer, Inc.. (6/22/21). "Press Release: PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader Sirion Biotech". Waltham, MA....
• [3] PerkinElmer, Inc.. (5/17/21). "Press Release: PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC". Waltham, MA....
• [4] Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA....
• [5] Sirion Biotech GmbH. (10/6/20). "Press Release: Mustang Bio Licenses LentiBOOST Technology from Sirion Biotech for the Development of MB-207 Lentiviral Gene Therapy". Worcester, MA & Martinsried....
• [6] Rentschler Biopharma SE. (5/19/20). "Press Release: Rentschler Biopharma Licenses Horizon Discovery's CHOSource Platform to Complement Cell Line Development Offering for Difficult-to-Express Proteins". Laupheim, Milford, MA & Cambridge....
• [7] Sirion Biotech GmbH. (4/7/20). "Press Release: Beam Therapeutics Licenses Sirion Biotech’s LentiBOOST Technology for Its CAR-T pipeline". Martinsried....
• [8] PerkinElmer, Inc.. (8/21/19). "Press Release: PerkinElmer Announces Leadership Succession Plan". Waltham, MA....
• [9] Sirion Biotech GmbH. (7/31/19). "Press Release: Gene and Cell Therapy Solutions Provider, Sirion Biotech Announces Record First Half 2019 Financial Results". Munich....
• [10] PerkinElmer, Inc.. (7/24/19). "Press Release: PerkinElmer and EverlyWell Announce Collaboration to Expand U.S. At-Home Health Test Market". Waltham, MA & Austin, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.